In a nutshell This study evaluated the association between statin (cholesterol-lowering drugs) use and survival outcomes in men with advanced prostate cancer (PC) undergoing androgen deprivation therapy (ADT). The data showed that statin use improved the survival outcomes in these patients. Some background Metastatic prostate cancer (PC) is a form of...
Read MoreProstate cancer Posts on Medivizor
Evaluating the functional and oncologic outcomes of combining whole-gland high-intensity focused ultrasound ablation with transurethral resection of the prostate in patients with prostate cancer.
In a nutshell This study evaluated the functional and oncologic outcomes of combining whole-gland high-intensity focused ultrasound ablation (HIFU) with transurethral resection of the prostate (TURP) in patients with prostate cancer (PCa). The data showed that the combination treatment of whole-gland HIFU and TURP improved the urinary outcomes in these...
Read MoreEvaluating the effectiveness and safety of olaparib with or without cediranib in patients with metastatic castration-resistant prostate cancer.
In a nutshell This study evaluated the effectiveness and safety of olaparib (Lynparza) with or without cediranib (Recentin) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that cediranib combined with olaparib significantly improved survival without cancer worsening compared with olaparib alone in these patients....
Read MoreEvaluating the effectiveness and safety of radium-223 dichloride treatment in real-world patients with metastatic castration-resistant prostate cancer.
In a nutshell The study evaluated the effectiveness and safety of radium-223 dichloride (Xofigo) treatment in real-world patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that radium-223 dichloride treatment was well tolerated and reduced pain in real-world patients with mCRPC spread to the bone. Some...
Read MoreEvaluating the effectiveness of degarelix with or without apalutamide before prostate surgery in patients with high-risk prostate cancer.
In a nutshell This study evaluated the effectiveness of degarelix (Firmagon) with or without apalutamide (Erleada) before radical prostatectomy (RP; prostate surgery) in patients with high-risk prostate cancer (PC). The data showed that degarelix plus apalutamide significantly improved the pathological response in these patients. Some background...
Read MoreComparing darolutamide, apalutamide and enzalutamide for treating non-metastatic castration-resistant prostate cancer.
In a nutshell The study compared the effectiveness of darolutamide (Nubeqa), apalutamide (Erleada), and enzalutamide (Xtandi) in treating non-metastatic castration-resistant prostate cancer (nmCRPC). The data showed that darolutamide, apalutamide, and enzalutamide were similarly effective and improved survival outcomes compared to placebo...
Read MoreEvaluating the effectiveness and safety of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.
In a nutshell This study evaluated the effectiveness and safety of rezvilutamide (Ariane) versus bicalutamide (Casodex) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that rezvilutamide in combination with ADT significantly improved the...
Read MoreEvaluating the effects of olaparib plus abiraterone regarding patient-reported outcomes in patients with metastatic castration-resistant prostate cancer patients
In a nutshell This study compared the effects on patient-reported outcomes (PROs) of using olaparib (Lynparza) plus abiraterone (Zytiga) versus placebo plus abiraterone for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The study found that adding olaparib to abiraterone in these patients did not...
Read MoreComparing the effectiveness and safety of prostate-only versus pelvic radiotherapy for patients with prostate cancer spread to nearby lymph nodes.
In a nutshell This study compared the safety and effectiveness of whole-pelvis radiotherapy (WPRT) and prostate-only radiotherapy (PORT) in patients with node-positive prostate cancer (PC) (PC that has spread to nearby lymph nodes). The study found that WPRT improves survival without relapse in these patients, with more short-term...
Read MoreEvaluating the effectiveness of adding short-term androgen deprivation therapy with or without pelvic lymph node treatment to prostate bed salvage radiotherapy in patients with resected prostate cancer.
In a nutshell This study evaluated the effectiveness and safety of adding short-term androgen deprivation therapy (ADT) with or without pelvic lymph node radiotherapy (PLNRT) to prostate bed salvage radiotherapy (PBRT) after surgery in patients with prostate cancer (PC). The study found that adding short-term ADT and PLNRT to PBRT significantly improved...
Read MoreEvaluating the benefits of radiotherapy dose escalation and the addition of short-term or long-term androgen deprivation therapy in men with localized prostate cancer.
In a nutshell This study evaluated the benefits of radiation therapy (RT) dose escalation and the addition of short-term (ST) or long-term (LT) androgen deprivation therapy (ADT) to RT in men with localized prostate cancer (PCa). The data showed that the addition of ST or LT-ADT to RT improved survival without metastasis in these patients,...
Read MoreEvaluating the long-term outcomes of radiotherapy added to standard therapy for men with metastatic prostate cancer.
In a nutshell The study investigated whether radiotherapy (RT) addedd to standard of care (SOC) treatment would be beneficial for men with metastatic (spread) prostate cancer (mPC). The study showed that adding RT to SOC improved the survival of men with low burden (defined as fewer than 10 lesions, no greater than 3cm in diameter) mPC. Some...
Read More